Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 36, n° 6
pages 956-958 (juin 1997)
Doi : 10.1016/S0190-9622(97)80280-0
Therapy

5-Fluorouracil iontophoretic therapy for Bowen's disease
 

Mark L. Welch a : MAJ, William J. Grabski b : LTC, Martha L. McCollough b : LTC, Henry G. Skelton c : CAPT, Kathleen J. Smith d : COL, Padman A. Menon d : CDR, Lawrence L. Anderson b : LTC
a Dermatology Service, Walter Reed Army Medical Center, Washington, Washington, D.C., Ft. Sam Houston, Texas, and Bethesda, Maryland, USA 
b Dermatology Service, Brooke Army Medical Center, Ft. Sam Houstonb, Washington, D.C., Ft. Sam Houston, Texas, and Bethesda, Maryland, USA 
c Dermatology Department, Armed Forces Institute of Pathology, Washington, Washington, D.C., Ft. Sam Houston, Texas, and Bethesda, Maryland, USA 
d Dermatology Service, Bethesda Naval Medical Center, Washington, D.C., Ft. Sam Houston, Texas, and Bethesda, Maryland, USA 

Abstract
Background:

Topical 5-fluorouracil (5-FU) is an accepted therapy for Bowen's disease. Recurrences with this method have been attributed to deep follicular involvement and poor patient compliance because of the prolonged treatment time required.

Objective:

We sought to determine whether iontophoresis of 5-FU is an effective therapy for Bowen's disease.

Methods:

Twenty-six patients with biopsy-proven Bowen's disease received eight 5-FU iontophoretic treatments in 4 weeks. Local excision was done 3 months after the last treatment. The specimens were step-sectioned and evaluated for any histologic evidence of bowenoid changes.

Results:

Only 1 of 26 patients showed histologic evidence of Bowen's disease 3 months after treatment.

Conclusion:

5-FU iontophoresis appears to be a safe, effective, and well-tolerated therapy for Bowen's disease.

The full text of this article is available in PDF format.

Top of the page

© 1997  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@